.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Pindolol - Generic Drug Details

« Back to Dashboard
Pindolol is the generic ingredient in two branded drugs marketed by Idt Australia Ltd, Mylan Pharms Inc, Nostrum Labs Inc, G And W Labs Inc, Purepac Pharm, Watson Labs, Sun Pharm Inds, Nostrum Labs, and Novartis, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for pindolol. Four suppliers are listed for this compound.

Summary for Generic Name: pindolol

Tradenames:2
Patents:0
Applicants:9
NDAs:14
Drug Master File Entries: see list10
Suppliers / Packaging: see list4
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: pindolol

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nostrum Labs
PINDOLOL
pindolol
TABLET;ORAL074474-001Oct 28, 1996DISCNNo► subscribe► subscribe
Sun Pharm Inds
PINDOLOL
pindolol
TABLET;ORAL074063-001Jan 27, 1994RXNo► subscribe► subscribe
Novartis
VISKEN
pindolol
TABLET;ORAL018285-001Sep 3, 1982DISCNNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: pindolol

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
VISKEN
pindolol
TABLET;ORAL018285-001Sep 3, 19823,471,515► subscribe
Novartis
VISKEN
pindolol
TABLET;ORAL018285-002Sep 3, 19823,471,515► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc